SecBot SecBot
8-K ·Filed Jul 20, 2026

PSNL

Personalis, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001193125-26-308488
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

PSNL shares should trade near the $16.25 deal price with a small spread reflecting closing risk and time value. Monitor the S-4 proxy filing for shareholder vote details and any regulatory developments. The deal structure (stock with cash option) introduces TEM stock price risk, if TEM falls below $46, PSNL can terminate. Spread-watching is warranted.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.34
T+0 close · Jul 20, 2026 · via day close
Latest settled
+18.82%
T+60 · $15.85
Vs SPY
+13.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 20 $13.34entry
  2. T+1 · 4mo ago +0.75%α −0.08% · $13.44
  3. T+5 · 4mo ago −11.69%α −11.27% · $11.78
  4. T+20 · 3mo ago +4.12%α +0.00% · $13.89
  5. T+60 · 5w ago +18.82%α +13.98% · $15.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Personalis (PSNL) announced a definitive agreement to be acquired by Tempus AI (TEM) for $16.25 per share in a stock transaction valued at $1.5B enterprise value net of Tempus' existing stake. The deal represents a 6% premium to Friday's close and a 28% premium to the 30-day VWAP, with closing expected in late 2026 or early 2027. Preliminary Q2 2026 revenue of $22.4M and 10,384 clinical tests (33% sequential growth) underscore the commercial momentum that drove the acquisition.

Key Facts

  • Acquisition price of $16.25 per share in a stock transaction (Tempus may elect cash up to 50% of consideration)
  • Total enterprise value of $1.5 billion, net of Tempus' existing ownership interest
  • 6% premium to Friday's closing price and 28% premium to unaffected 30-day VWAP
  • Preliminary Q2 2026 revenue of $22.4 million and 10,384 clinical tests (33% sequential growth)
  • Closing expected in late 2026 or early 2027, subject to Personalis shareholder approval and regulatory clearances
  • Tempus has the option to pay cash, capped at 50% of consideration, financed with cash on hand and credit facilities

Financial Impact

Enterprise value of $1.5B; $16.25 per share consideration; preliminary Q2 revenue $22.4M

revenueclinical test volumemarket capitalization

Risk Factors

  • Shareholder approval may not be obtained
  • Regulatory approvals could be delayed or denied
  • Tempus stock price falling below $46 per share gives Personalis the right to terminate the merger agreement
  • Integration risks and potential disruption to business operations during the pendency

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-308488
Document: d68794dex991.htm0001193125-26-308488
Document: 0001193125-26-308488-index-headers.html0001193125-26-308488
Document: 0001193125-26-308488-index.html0001193125-26-308488
Document: 0001193125-26-308488.txt0001193125-26-308488
8-K Data (Synthetic)0001193125-26-308488

Track record

29 reports on PSNL

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +18.82% at T+60 after the Jul 20, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.16 Now $14.80 −2.34% settles Feb 12
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $15.71 Now $14.80 −5.79% settles Feb 11
  3. Nov 12, 20264d ago 425 Neutral 4/10 Entry $15.86 Now $14.80 −6.68% settles Feb 10
  4. Nov 6, 202610d ago 425 Neutral 3/10 Entry $15.95 Now $14.80 −7.21% settles Feb 5
  5. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $15.55 Now $14.80 −4.82% settles Feb 3
  6. Nov 3, 202613d ago 425 Neutral 3/10 Entry $15.79 Now $14.80 −6.27% settles Feb 2
  7. Oct 30, 202617d ago 425 Neutral 4/10 Entry $15.76 Now $14.80 −6.09% settles Jan 29
  8. Oct 21, 202626d ago DEFM14A Neutral 5/10 Entry $15.82 Now $14.80 −6.45% settles Jan 20
  9. Oct 20, 202627d ago 425 Neutral 4/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
  10. Oct 20, 202627d ago 425 Neutral 5/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
Showing 10 of 29

US Market Status

Market Closed · Opens in 8h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026